Form 8-A12B - Registration of securities [Section 12(b)]
26 Dicembre 2023 - 10:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-A
FOR
REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF
THE SECURITIES EXCHANGE ACT OF 1934
AMNEAL
PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
|
93-4225266 |
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
|
|
|
400 Crossing Blvd |
|
|
Bridgewater, New Jersey |
|
08807 |
(Address of principal executive offices) |
|
(Zip code) |
Securities to be registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class
to be so registered |
|
Name of each exchange on which
each class is to be registered |
Class A Common Stock, par value $0.01 per share |
|
The Nasdaq Stock Market LLC |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General
Instruction A.(c) or (e), check the following box. ☒
If this form relates to the registration of a class of securities pursuant to
Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐
If this
form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐
Securities Act registration statement or Regulation A offering statement file number to which this form relates:
Not applicable
Securities to be registered pursuant to Section 12(g) of the Act:
None
EXPLANATORY NOTE
Amneal Pharmaceuticals, Inc. (the Registrant) is filing this Registration Statement on Form 8-A in
connection with the transfer of the listing of its Class A Common Stock, par value $0.01 per share (the Common Stock), from the New York Stock Exchange (the NYSE) to The Nasdaq Stock Market LLC (Nasdaq). The
Registrant expects the listing and trading of its Common Stock on the NYSE to cease at the close of trading on December 26, 2023 and that trading will begin on Nasdaq at market open on December 27, 2023.
Item 1. Description of Registrants Securities to be Registered
The description of the Registrants Common Stock included in Exhibit
99.1 to the Registrants Current Report on Form 8-K (File No. 001-38485), filed with the Securities and Exchange Commission on November 8, 2023, is
incorporated herein by reference, except that any reference to the NYSE is hereby amended to refer to Nasdaq.
Item 2. Exhibits
Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed, because no
other securities of the Registrant are registered on Nasdaq and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be
signed on its behalf by the undersigned, thereto duly authorized.
|
|
|
|
|
|
|
Date: December 26, 2023 |
|
|
|
Amneal Pharmaceuticals, Inc. |
|
|
|
|
|
|
|
|
By: |
|
/s/ Anastasios Konidaris |
|
|
|
|
|
|
Name: Anastasios Konidaris |
|
|
|
|
|
|
Title: Executive Vice President and Chief Financial Officer
(Principal Financial and Accounting Officer) |
Grafico Azioni Amneal Pharmaceuticals (NYSE:AMRX)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Amneal Pharmaceuticals (NYSE:AMRX)
Storico
Da Nov 2023 a Nov 2024